prediction
Divesting Frontage may to some extent affect Tigermed's global layout and cross-border drug R&D competitiveness.
A prediction by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.
因此,剝離方達可能會在一定程度上影響泰格醫藥的全球佈局和跨境藥物研發競爭力。
Discussion
Related claims
Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.瑞銀 · predictionFrontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.瑞銀 · statementTigermed announced it will participate in the privatization and business split of Frontage Holdings (01521) through its wholly-owned subsidiary Hong Kong Tigermed.瑞銀 · statementTigermed announced it will participate in the privatization and business split of Frontage Holdings through its wholly-owned subsidiary Hong Kong Tigermed.瑞銀 · statementIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.瑞銀 · predictionIf the transaction is completed, Tigermed can also divest non-core businesses, including overseas laboratories, CMC and genomics, to focus more on clinical CRO services.瑞銀 · prediction
More claims by 瑞銀
Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.predictionTigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.statementIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.predictionFrontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.statementAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.statement
All claims by 瑞銀